Investment Rating - The report maintains a "Hold" rating for Ping An Good Doctor (1833.HK) with a target price of HKD 14.0, indicating a potential downside of 5% from the current price of HKD 14.8 [2][4]. Core Insights - The company has shown steady revenue and net profit growth in Q3 2025, with an expected annual revenue growth of approximately 15% and a net profit margin of around 5% [2][8]. - The recent stock price correction has brought the shares into a relatively reasonable range, supporting the "Hold" rating [2]. - The new management team is expected to accelerate collaboration with the group and explore new business models, enhancing the company's long-term growth potential [8]. Financial Performance Summary - For 2023, the company reported a revenue of RMB 4,674 million, with a projected increase to RMB 5,525 million in 2025, reflecting a year-on-year growth of 14.9% [3][9]. - The net profit is expected to turn positive in 2024, reaching RMB 81 million, and further increasing to RMB 247 million in 2025 [3][9]. - The adjusted net profit for Q3 2025 was RMB 51.39 million, with an adjusted net profit margin of 4.2% [8]. Business Segment Performance - The F&B segment and B2B health services have shown robust growth, with a 21.5% increase in revenue for the first nine months of 2025 [8]. - The number of users in home care services has increased by 41% compared to the end of 2024, indicating strong demand in this area [8]. Management Changes - The appointment of new executives with extensive consulting experience is anticipated to drive the company's strategic initiatives and operational efficiency [8].
平安好医生（01833）：3Q25“F+B”端增长稳健，养老服务用户数维持快速增长